MIRM Mirum Pharmaceuticals, Inc. Feb 26 2026 Leerink Maintains Outperform
Three major firms maintained Outperform on Mirum Pharmaceuticals, Inc. (MIRM) on February 26, 2026, keeping analyst conviction despite a sharp intraday drop. The phrase MIRM analyst rating frames this update: Leerink Partners, Evercore ISI, and RBC Capital each left their ratings unchanged while responding differently to the stock move. Leerink cut its price target to $118, while RBC and Evercore defended the pullback as noise and a buying opportunity. These actions drove a 13–15% retracement and matter for investors tracking consensus and price targets right now.
MIRM analyst rating summary for Feb 26, 2026
On February 26, 2026, all three firms maintained Outperform on MIRM. Leerink Partners issued note at 10:52 AM, Evercore ISI at 10:50 AM, and RBC Capital at 10:40 AM. The coordinated maintenance signals ongoing analyst confidence even as price targets and tone varied.
Individual analyst actions and notes
Leerink Partners kept an Outperform but lowered the price target to $118 and flagged near-term risk, per StreetInsider. Evercore ISI maintained Outperform and described the selloff as “noise in a volatile tape.” RBC Capital maintained Outperform and called the drop a buying opportunity ahead of de-risked catalysts.
MIRM analyst rating and price movement connection
The rating maintenance coincided with a steep intraday pullback: Leerink noted a 15.0% ($14.02) move, Evercore cited 14.34% ($13.48), and RBC referenced 13.22% ($12.55). These percent moves show how analyst commentary can amplify short-term volatility and influence investor flow.
Price targets and what the Leerink cut means
Leerink’s $118 target is the only explicit price target change in this batch and serves as a recalibration of near-term expectations. A lower price target with an unchanged rating signals confidence in the thesis, but more conservative valuation assumptions or timing for key catalysts.
Implications for investors tracking MIRM analyst rating
Maintained Outperform ratings mean analysts expect MIRM to beat peers over their coverage window. Investors should treat the notes as a mix of confidence and caution: the ratings support upside, while Leerink’s PT cut and the price pullback increase near-term risk.
Historical context and near-term outlook
These three firms have followed Mirum through product and pipeline milestones and remain bullish overall. The current cluster of maintained Outperform calls suggests consensus support, but the market will watch catalysts and trial news to validate the analysts’ views.
Final Thoughts
Key takeaways on the MIRM analyst rating cluster on February 26, 2026: three notable firms—Leerink Partners, Evercore ISI, and RBC Capital—kept Outperform on Mirum Pharmaceuticals, Inc., even as the stock fell roughly 13–15% intraday. Leerink trimmed its price target to $118, adding a valuation caveat while preserving its positive stance. Evercore and RBC framed the drop as volatility and a buying chance ahead of de-risked catalysts. Investors should weigh analyst conviction against the price target cut and the recent volatility. Meyka AI rates MIRM with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and we are not financial advisors. For real-time tracking and detailed alerts, see the MIRM profile on Meyka AI at MIRM on Meyka.
FAQs
What changed in the MIRM analyst rating on February 26, 2026?
On February 26, 2026, Leerink Partners, Evercore ISI, and RBC Capital all maintained Outperform on MIRM. Leerink lowered its price target to $118, while Evercore and RBC defended the stock amid a volatile pullback.
How should investors interpret the Leerink price target cut?
Leerink’s cut to $118 with an unchanged Outperform suggests revised valuation timing or assumptions, not a lost thesis. The move signals caution on timing, while still backing Mirum’s longer term upside.
Does the maintained Outperform mean buy now?
Maintained Outperform is a positive analyst view, but not a direct buy signal. Combine the MIRM analyst rating with price action, catalysts, and your risk profile before acting.
How does Meyka AI view MIRM after these notes?
Meyka AI tracks the coverage and assigns MIRM a B+ grade based on sector, growth, benchmarks, and analyst consensus. This reflects balanced upside potential and near-term risk but is not financial advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.